
Before the year is over, Novo Nordisk will have submitted hemophilia drug concizumab for review by regulatory authorities, the company reports in its first quarterly report for 2022 on Friday.
The expectation is based on results from a phase III study, which has investigated the drug as a preventive treatment for people with the bleeding disorders, hemophilia A and B, with inhibitors.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app